.png)
Consumers who paid any amount of money for retail purchases of Aurobindo Irbesartan medication from Jan. 1, 2016, to the present may be eligible to claim a cash payment from a class action settlement.
Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC agreed to pay $2 million to resolve a class action lawsuit alleging certain irbesartan medications they manufactured, supplied, distributed, marketed or sold may have contained nitrosamine impurities, which are probable human carcinogens.
The settlement is part of a larger multidistrict litigation, In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation. There is also a $11,365,489.80 Hetero Valsartan settlement.
Who can file a claim?
Class members must meet all of the following criteria:
- They are an individual in the United States, its territories or possessions.
- They paid any amount of money for retail purchases of Irbesartan finished drug formulations manufactured using the Aurobindo Irbesartan active pharmaceutical ingredient and produced using Aurobindo’s IC Route of Synthesis.
- They made the purchase(s) between Jan. 1, 2016, and the present.
This includes anyone who paid out of pocket for Aurobindo Irbesartan, whether through copays, coinsurance or full retail price. Purchases made on behalf of someone else, such as a dependent, may also qualify if the claimant paid for the medication.
Class members can check the National Drug Code on their prescription bottle or pharmacy records to determine if their medication qualifies. Qualifying NDC codes include 60429-640-90, 60429-641-30, 60429-641-90, 60429-642-30, 60429-642-90, 69367-119-01, 69367-119-03, 69367-120-01, 69367-120-03, 69367-121-01 and 69367-121-03.
Pharmacy benefit managers do not qualify for this settlement.
How much can class members get?
The settlement administrator will base payments to eligible class members on the quantity of qualifying Aurobindo Irbesartan they purchased. The standard award is $10.71 for each 30-day supply of qualifying Aurobindo Irbesartan purchased up to a maximum of $128.52 per consumer.
However, class members who provide documentation showing they paid more than $10.71 for a 30-day supply out of pocket may receive a payment above the $10.71 per 30-day supply and $128.52 total cap.
There is no cap for documented claims above the standard amount; however, the settlement caps total payments to consumers at 70% of the net settlement fund after deductions for attorneys’ fees, expenses, administration costs and service awards. If the total of all valid claims exceeds this cap, the settlement administrator will reduce payments proportionally.
How to claim a settlement payout
Class members can file a claim online or download and print a PDF claim form to mail to the settlement administrator. The claim deadline is June 2, 2026.
Settlement administrator's mailing address: Sartan Medication Settlement Administrator, PO Box 3376, Baton Rouge, LA 70821
The settlement website does not specify payment options.
Is proof or documentation required to submit a claim?
- For claims up to $10.71 per 30-day supply and $128.52 total, class members do not need to submit documentation. However, the settlement administrator may request proof to verify claims.
- For claims above $10.71 per 30-day supply or above $128.52 total, class members must submit documentation, such as pharmacy receipts or records.
$2 million settlement fund breakdown
The $2,000,000 settlement fund includes:
- Settlement administration costs: To be determined
- Attorneys' fees: Up to $666,667
- Attorneys' expenses: To be determined
- Service awards to class representatives: $1,000 for the consumer representative plaintiff and $3,000 each for the two TPP representative plaintiffs ($7,000 total)
- Payments to eligible class members: Remaining funds
Important dates
- Deadline to file a claim: June 2, 2026
- Exclusion (opt-out) deadline: June 2, 2026
- Fairness hearing: June 30, 2026
When is the Aurobindo Irbesartan settlement payout date?
The settlement administrator will distribute payments after the court grants final approval of the settlement.
Why is there a class action settlement?
The action lawsuit alleged Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC violated state laws by manufacturing, distributing, selling or dispensing Irbesartan or Irbesartan-containing drugs contaminated with probable human carcinogens in the form of N-nitrosodimethylamine or NDEA.
The defendants denied any wrongdoing or liability, and the court has not decided whether the claims have merit. The parties agreed to settle to resolve the claims and avoid further litigation.
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.svg)